Equities Analysts Issue Forecasts for XBIO FY2026 Earnings

Xenetic Biosciences Inc (NASDAQ:XBIO) – Research analysts at HC Wainwright issued their FY2026 earnings estimates for Xenetic Biosciences in a note issued to investors on Monday, November 11th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.64) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.75) EPS.

Xenetic Biosciences Price Performance

Shares of NASDAQ XBIO traded up $0.06 during midday trading on Thursday, hitting $3.71. The stock had a trading volume of 517 shares, compared to its average volume of 11,228. The firm has a market cap of $5.72 million, a P/E ratio of -1.37 and a beta of 2.25. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20. The company’s 50-day simple moving average is $3.89 and its 200 day simple moving average is $3.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, hitting the consensus estimate of ($0.83). The firm had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $0.54 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 47.21%.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.